Memorial Sloan Kettering Cancer Center

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Myeloma
Leukemia
Lymphoma
Hematologic Transplantation and Malignancies
Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic
Skin
Head and Neck
Brain
General Oncology
Palliative Care
MPN
COVID-19
Events

Playback speed

10 seconds

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Untreated Adult Pts Selected for RARA+ AML Who Are Ineligible for Standard Induction Therapy (SELECT-AML-1)

By EHA 2022 Conference Coverage FEATURING Eytan Stein

206 views

June 21, 2022

Comments 0

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Feat. H. Rugo

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Leukemia

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

298 views

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

SOHO 2023 Eleventh Annual Meeting

J. Park

83 views

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

SOHO 2023 Eleventh Annual Meeting

E. Stein

39 views

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

International CML Foundation

M. Mauro

112 views

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

ASH 2022 Conference Coverage

E. Stein

167 views

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Un…

EHA 2022 Conference Coverage

E. Stein

206 views

Expert Perspectives on Treating High-Risk and R/R AML

PleXus Communications

E. Stein

141 views

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With …

ecancer

M. Mauro

26 views

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-…

ASH 2021 Conference Coverage on VuMedi

E. Stein

130 views

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

University of Miami's 2nd Biennial Miami Leukemia Symposium

E. Stein

228 views

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

343 views

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

174 views

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

78 views

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

27 views

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

32 views

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

16 views

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

29 views

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Indy Hematology Review

M. Tallman

1.8K views

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…

Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

M. Mauro

16 views

Front-line Strategies in Ph-negative ALL

Memorial Sloan Kettering Cancer Center

M. Geyer

172 views

Updates and Challenges in the Management of Chronic Myeloid Leukemia…

Memorial Sloan Kettering Cancer Center

M. Mauro

146 views

Multi-drug Resistant and Intolerant CML: What to Do?

Memorial Sloan Kettering Cancer Center

M. Mauro

168 views

IDH Inhibitors in AML

Memorial Sloan Kettering Cancer Center

E. Stein

166 views